Target Name: CD8B
NCBI ID: G926
Review Report on CD8B Target / Biomarker Content of Review Report on CD8B Target / Biomarker
CD8B
Other Name(s): CD81B M-2 variant | LEU2 | CD8 antigen beta polypeptide 1 | CD8B variant 3 | T lymphocyte surface glycoprotein beta chain | T-cell surface glycoprotein CD8 beta chain (isoform 1) | CD8b | CD8b molecule, transcript variant 2 | CD8B1 | CD8b molecule, transcript variant 3 | LYT3 | CD8B variant 2 | CD8b molecule, transcript variant 4 | LY3 | CD8B variant 4 | P37 | T-cell surface glycoprotein CD8 beta chain (isoform 6) | CD8 antigen, beta polypeptide 1 (p37), transcript variant 1 | CD8B1 variant 1 | CD8 beta chain | CD8B variant 6 | CD8B_HUMAN | CD8b molecule, transcript variant 6 | T-cell surface glycoprotein CD8 beta chain | T-cell surface glycoprotein CD8 beta chain (isoform 4) | CD8b molecule | Ly-3 | CD8 antigen, beta polypeptide 1 (p37) | CD8beta | Ly-3 homolog | Antigen CD8B | T-cell surface glycoprotein CD8 beta chain (isoform 3) | T-cell surface glycoprotein CD8 beta chain (isoform 2)

CD81B M-2 Variant: A Promising Drug Target and Biomarker

Introduction

CD81B M-2 variant, also known as CD81B M-2, is a cell surface protein that is expressed in various tissues and organs, including the immune system, gastrointestinal tract, and nervous system. Its function is not well understood, but it is known to play a role in the immune response and inflammation.

Recent studies have identified CD81B M-2 as a potential drug target and biomarker for various diseases, including autoimmune disorders, cancer, and neurodegenerative diseases. In this article, we will explore the CD81B M-2 variant in greater detail, including its expression, function, and potential as a drug target and biomarker.

Expression and Localization

CD81B M-2 is a 21-kDa transmembrane protein that is expressed in various tissues and organs, including the brain, spinal cord, skeletal muscles, liver, and gastrointestinal tract. It is mainly localized to the endoplasmic reticulum (ER) and appears to play a role in regulating the immune response and inflammation.

CD81B M-2 is a type-I transmembrane protein, which means that it spans the entire cell membrane and is associated with various cellular processes, including the regulation of adhesion, migration, and signaling pathways. Its localization to the ER suggests that it may be involved in the regulation of protein synthesis and degradation, as well as in the formation of intracellular signaling complexes.

Function and Potential as a Drug Target

CD81B M-2 has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. Several studies have shown that CD81B M-2 plays a role in the regulation of immune responses, including T cell development and function.

CD81B M-2 has also been shown to be involved in the regulation of cell survival and apoptosis, which are critical processes that are often disrupted in cancer and neurodegenerative diseases. Additionally, its expression has been associated with various diseases, including autoimmune disorders, cancer, and neurodegenerative diseases, which further supports its potential as a drug target.

CD81B M-2 has been shown to interact with various signaling pathways, including TGF-灏?, NF-kappa-B, and PI3K/AKT signaling pathways. These signaling pathways are involved in various cellular processes, including cell growth, differentiation, and inflammation. Therefore, targeting CD81B M-2 may be a promising strategy for the development of new treatments for various diseases.

CD81B M-2 has also been shown to be involved in the regulation of cytokine signaling, which is critical for the regulation of immune responses and inflammation. Therefore, targeting CD81B M-2 with drugs that can modulate cytokine signaling may be a promising strategy for the treatment of autoimmune disorders and other inflammatory diseases.

Biomarker Potential

CD81B M-2 has also been shown to be a potential biomarker for various diseases, including cancer and neurodegenerative diseases. Its expression has been associated with the development and progression of these diseases, which further supports its potential as a biomarker.

Studies have shown that CD81B M-2 is overexpressed in various tissues and organs, including cancer cells, neurodegenerative disease mouse models, and patient samples. Additionally, its expression has been shown to be associated with poor prognosis in various diseases, including cancer (7 ). Therefore, targeting CD81B M-2 with drugs that can reduce its expression may be a promising strategy for the treatment of various diseases.

Conclusion

CD81B M-2 variant is a cell surface protein that is expressed in various tissues and organs, including the immune system, gastrointestinal tract, and nervous system. Its function is not well understood, but it is known to play a role in the immune response and inflammation. In recent years, studies have shown that CD81B M-2 is a potential drug target and biomarker for various diseases, including autoimmune disorders, cancer, and neurodegenerative diseases. Its potential as a drug target is based on its unique structure and its involved in various cellular processes, including the regulation of immune responses, cell survival and apoptosis, and cytokine signaling. Its potential as a biomarker is based on its association with the development and progression of various diseases, including cancer and neurodegenerative diseases. Therefore, targeting CD81B M-2 with drugs that can modulate its expression may be a promising strategy for the treatment of various diseases.

Protein Name: CD8b Molecule

Functions: Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. In T-cells, functions primarily as a coreceptor for MHC class I molecule:peptide complex. The antigens presented by class I peptides are derived from cytosolic proteins while class II derived from extracellular proteins. Interacts simultaneously with the T-cell receptor (TCR) and the MHC class I proteins presented by antigen presenting cells (APCs). In turn, recruits the Src kinase LCK to the vicinity of the TCR-CD3 complex. A palmitoylation site in the cytoplasmic tail of CD8B chain contributes to partitioning of CD8 into the plasma membrane lipid rafts where signaling proteins are enriched. Once LCK recruited, it initiates different intracellular signaling pathways by phosphorylating various substrates ultimately leading to lymphokine production, motility, adhesion and activation of cytotoxic T-lymphocytes (CTLs). Additionally, plays a critical role in thymic selection of CD8+ T-cells

The "CD8B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD8B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15